Baird Cuts Price Target on Enanta Pharma (ENTA) Despite Bottom-Line Beat

February 9, 2016 7:28 AM

Baird remains Neutral on Enanta Pharmaceuticals (NASDAQ: ENTA), and cut the price target to $22.00 (from $36.00), following the company's ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found